Progesterone: A Comprehensive Reference
1. Identity
1.1 Chemical Names and Classification
Progesterone is a naturally occurring pregnane steroid also known by its systematic IUPAC name pregn-4-ene-3,20-dione. It is a C-21 steroidal sex hormone involved in the female menstrual cycle, pregnancy, and embryogenesis, and belongs to the class of hormones called progestogens, of which it is the major naturally occurring human representative. Progesterone is the most important progestogen in the body.
Structurally, it has a double bond (4-ene) between the C4 and C5 positions, and two ketone groups (3,20-dione), one at the C3 position and the other at the C20 position. Like other steroids, progesterone consists of four interconnected cyclic hydrocarbons. Its structure is more similar to the structure of testosterone, differing only in the substituent on C17 (an acetyl group instead of a hydroxyl group), than to female sex hormones such as estrone or estriol. Progesterone is a natural steroid hormone that has six chiral centers, and because it can be synthesized from a natural product, a commercially available optically pure form is called nat-progesterone.
1.2 Natural Endogenous Sources and Biosynthesis
Progesterone is primarily produced by endocrine glands. In individuals with ovaries, the corpus luteum — a temporary structure forming after ovulation — is the main site of synthesis during the menstrual cycle. During pregnancy, the placenta becomes a significant source, taking over much of its production to support the developing fetus. The adrenal glands also contribute to progesterone production, though to a lesser extent. Progesterone is biosynthesized from pregnenolone, a derivative of cholesterol.
Progesterone is also synthesized by the nervous system by neurons and glia — constituting neurosteroid action — and all enzymes necessary for the conversion of cholesterol to pregnenolone and subsequently to progesterone are widely distributed within the brain. Progesterone can be further metabolized to other neuroactive steroids, of which allopregnanolone is the most important.
1.3 Commercial Production
Progesterone is commercially produced by semisynthesis. Two main routes are used: one from yam diosgenin first pioneered by Marker in 1940, and one based on soy phytosterols scaled up in the 1970s. Additional semisyntheses of progesterone have also been reported starting from a variety of other steroids.
1.4 Common Preparations and Dosage Forms
Progesterone can be taken by mouth, through the vagina, and by injection into muscle or fat, among other routes. Key preparations include:
- Oral micronized progesterone (OMP): For a long time progesterone could not be used in clinical applications because of rapid liver inactivation after oral administration; an oral micronized preparation is now available that produces adequate plasma and tissue levels.
- Vaginal formulations: Available as gels, pessaries, and suppositories. The vaginal route delivers high local drug concentrations.
- Intramuscular (IM) injection: Progesterone in oil is used parenterally, especially in assisted reproductive technology (ART).
- Topical gel: Progesterone is approved under the brand name Progestogel as a 1% topical gel for local application to the breasts to treat breast pain in certain countries, and is not approved for systemic therapy in that form.
Progesterone is hydrophobic, having an aqueous solubility of only 0.007 mg/mL, which is a key determinant of its formulation challenges and route-dependent bioavailability.
2. Historical and Traditional Use
2.1 Early Scientific Discovery
Research leading to the discovery and characterization of progesterone (P4) began in the mid-1800s and followed a path carved by key discoveries in the burgeoning field of endocrinology. The primary observation leading to the discovery of P4 was that the maternal corpus luteum is necessary for the establishment and maintenance of pregnancy. Experiments in animal models exploring the consequence of corpus luteum ablation and the effects of treatment with corpus luteum extract formed the basis for the eventual isolation and characterization in the 1930s of the corpus luteum hormone, initially referred to as progestin and subsequently named progesterone.
The modern history of progesterone begins with the first book-length description of the female reproductive system including the corpus luteum, and later with the Nobel Prize winner Adolf Butenandt, who took a crucial step when he succeeded in converting pregnanediol into a chemically pure form of progesterone — the corpus luteum hormone. It was first prescribed in 1934.
2.2 Early Medical Applications
Progestogen treatment has traditionally and predominately been used in maintaining pregnancy, the prevention of preterm labor, various gynecological pathologies, and in lowering the negative effects of menopause.
The deficient production of progesterone was shown first to be the cause of the luteal-phase deficiency responsible for infertility and early pregnancy loss due to inadequate secretory transformation of the endometrium. Later, progesterone was confirmed to be the best and safest method of providing luteal-phase support in assisted reproductive technology.
Historically, progesterone has been widely used in the treatment of premenstrual syndrome.
2.3 Evolution of Oral Administration
More modern clinical studies of oral progesterone demonstrating elevated plasma levels and end-organ responses — specifically progestational endometrial changes — were published between 1980 and 1983. Up to this point, many clinicians and researchers apparently still thought that oral progesterone was inactive. It was not until almost half a century after the introduction of progesterone in medicine that a reasonably effective oral formulation was marketed.
3. Key Constituents, Metabolites, and Mechanisms of Action
3.1 Classical (Genomic) Mechanism
Progesterone has been thought to exert its effects through the progesterone receptor (PR), a member of the nuclear steroid hormone superfamily, acting through specific progesterone response elements (PRE) within the promoter region of target genes to regulate transcription. As a potent agonist of the nuclear progesterone receptor (nPR) — with an affinity of KD = 1 nM — the resulting effects on ribosomal transcription play a major role in regulation of female reproduction. From a receptor pharmacology standpoint, the mechanism of progesterone action implicates the classical PR (e.g., PR-B or its N-terminally truncated variant, PR-A).
Progesterone and its associated metabolites are powerful biological agents through genomic action by the progesterone nuclear receptor, with a finely tuned regulatory role throughout pregnancy, from conception until delivery.
3.2 Non-Genomic (Extra-Nuclear) Mechanisms
Although the paradigmatic role for progesterone is reproductive function, it has also been shown to exert significant extra-reproductive actions via multiple non-genomic signaling pathways. These functions include immunomodulation, inhibition of cholesterol biosynthesis, and neuroprotection.
Extra-nuclear, non-classical mechanisms of action have also been identified, including steroid interactions with membrane receptors — oxytocin receptors and γ-aminobutyric acid (GABAA) receptors — and the induction of a direct relaxing effect on uterine contractility by blockage of calcium influx.
In addition to nuclear and membrane steroid hormone receptors such as PR, mPR, PGRMC1/2, ER, AR, CAR, and PXR, progesterone can bind to GABAA receptors, NMDA receptors, and Sigma-1 and -2 receptors.
3.3 Biologically Active Metabolites
Progesterone and two important metabolites — namely allopregnanolone (3α,5α-tetrahydroprogesterone) and 3α,5α-tetrahydrodeoxycorticosterone — exert neuroprotective effects.
In the brain, progesterone is converted to a metabolite, allopregnanolone (ALLO), whose beneficial effects may equal or exceed those of progesterone itself in certain contexts. ALLO does not bind the nuclear progesterone receptor, suggesting it acts through non-classical pathways. ALLO has effects on GABAA and pregnane X receptors, as well as on the mitochondrial permeability transition pore.
3.4 Neuroactive Steroid Actions
Changes in concentrations of neuroactive steroids are accompanied by changes in the expression of GABAA receptor subunits responsible for their affinity for these substances. All these processes require precise synchronization, the disruption of which can lead not only to premenstrual syndrome but also to other neuropsychological consequences in physiological and pathophysiological situations such as pregnancy, childbirth, menopause, stress, and disease.
Progesterone and allopregnanolone also have the ability to modulate further neurotransmitter systems, such as the serotonergic, cholinergic, and dopaminergic systems.
3.5 Reproductive System Actions
Progesterone prepares the endometrium for implantation of the oocyte, prevents ovulation, and facilitates increased glandular tissue in the mammary glands.
3.6 Antiestrogenic and Other Steroid-Receptor Actions
Progesterone (P), the natural hormone, binds to its specific receptors to induce specific progestational effects. In addition to this binding, P is able to interfere with the binding sites of other steroids. Therefore the natural hormone exhibits antiestrogenic activity, anti-androgenic activity, and also exerts anti-mineralocorticoid effects.
4. Scientific Evidence by Area of Use
4.1 Pregnancy Maintenance: Threatened Miscarriage
Progesterone is essential for the maintenance of pregnancy. Several small trials have suggested that progesterone supplementation may reduce the risk of miscarriage in women with recurrent or threatened miscarriage.
The STOP trial, a placebo-controlled randomized clinical trial, evaluated progesterone use in women with threatened miscarriage. The live birth rates were 82.4% in the intervention group and 84.2% in the placebo group (risk ratio 0.98, 95% CI 0.88–1.09; P = 0.683). Among women with at least one previous miscarriage, live birth rates were 80.6% versus 84.4% (RR 0.95, 95% CI 0.82–1.11; P = 0.550). No significant effect was seen from progesterone in women with two (RR 1.28, 95% CI 0.96–1.72) or more previous miscarriages (RR 0.79, 95% CI 0.53–1.19).
A network meta-analysis included seven randomised trials involving 5,682 women. Across the treatment arms, three used vaginal micronized progesterone, three used dydrogesterone, one used oral micronized progesterone, one used 17-α-hydroxyprogesterone, and six used placebo.
A Cochrane review found that treatment of preterm birth with the use of progestogens compared to placebo or no treatment may have little or no effect in reducing the rate of preterm birth (RR 0.86, 95% CI 0.52 to 1.44; 5 trials; 588 women; low-quality evidence).
Progesterone has been shown to prevent miscarriage in those with vaginal bleeding early in their current pregnancy and having a previous history of miscarriage.
Evidence strength: Moderate; results are mixed by population and route. Benefit appears most supported for women with prior pregnancy loss and current vaginal bleeding, not for threatened miscarriage in the general population.
4.2 Preterm Birth Prevention
Miscarriage affects up to 20% of pregnant women, and preterm births constitute about 7–12% of all births but are over-represented in terms of perinatal morbidity and mortality.
A meta-analysis evaluated vaginal progesterone in women with singleton pregnancies and a short cervix (less than 25 mm). The study population consisted of women with singleton pregnancies and a short cervix on ultrasound, assigned into the progesterone group (n = 1,368) and the placebo group (n = 1,373), with treatment beginning after diagnosis of short cervix until delivery.
The use of progestogens is recommended in women with threatened miscarriages who have experienced previous miscarriage, as luteal phase support in women undergoing assisted reproduction, and in women with short cervix.
Evidence strength: Moderate-to-strong for vaginal progesterone in women with a sonographically short cervix; more limited for other clinical contexts.
4.3 Luteal Phase Support in Assisted Reproductive Technology (ART)
Progesterone is used for luteal phase support in assisted reproductive technologies (ART), for treating threatened miscarriage — especially in women with a history of one or more previous events or current early pregnancy bleeding — and for endometrial protection during menopausal hormone therapy (MHT).
Progesterone has been confirmed to be the best and safest method of providing luteal-phase support in assisted reproductive technology.
Evidence strength: Strong; progesterone supplementation in ART is considered standard clinical practice, supported by extensive trial data and endorsed by major reproductive medicine bodies.
4.4 Menopausal Hormone Therapy (MHT) and Endometrial Protection
Natural progesterone used in hormone therapy prevents endometrial hyperplasia from estrogens while helping relieve vasomotor symptoms and improving quality-of-life measures.
Although the oral bioavailability of progesterone is not high, the PEPI (Postmenopausal Estrogen/Progestin Interventions) trial convincingly demonstrated that progesterone offers endometrial protection in women receiving estrogens to treat menopausal symptoms.
Clinical trials have shown that 100 mg oral progesterone daily, 200 mg oral progesterone sequentially, or 100 mg vaginal progesterone every second day effectively protect the endometrium from the stimulatory effects of oestrogen.
As the transformation dose for progesterone is 2,000 mg per cycle, patients should receive either 100 mg/day continuously or 200 mg/day sequentially for a period of 12–14 days every cycle to ensure satisfactory secretory transformation of the endometrium in women previously treated with estrogens.
Evidence strength: Strong for endometrial protection; well-supported by multiple randomized and observational studies.
4.5 Breast Safety in Menopausal Hormone Therapy
MHT containing micronized progesterone has a significantly lower breast cancer risk than formulations containing synthetic progestins. Micronized progesterone does not appear to attenuate the cardiovascular benefits of oestrogen.
Observational data suggest a safer profile of natural progesterone (P4) versus progestins with respect to cardiovascular and breast cancer outcomes. Risk of venous thromboembolism and breast cancer does not appear to increase with use of P4 plus estrogens, as has been shown with synthetic progestins plus estrogens in large observational studies, and no detrimental effects of P4 in HT have been found on outcomes related to cardiovascular disease or cognition.
The KEEPS (Kronos Early Estrogen Prevention Study) report not only described positive effects of progesterone on cognitive functions but also described a protective effect for the cardiovascular system; at the same time, the risk of breast cancer was not increased in women receiving either placebo or 0.45 mg conjugated equine estrogen plus 200 mg progesterone for 12 days, or 50 µg estradiol per day via patch together with 200 mg progesterone for 12 days. Rates for endometrial cancer, stroke, myocardial infarction, and thromboembolism were also the same in all three groups.
Data suggest that micronized progesterone in MHT is safer for the breast than synthetic progestins, while protection of the endometrium appears to be less effective with some formulations. However, comparative randomized trial data are lacking.
Evidence strength: Moderate; largely observational rather than large randomized controlled trial data; the ongoing PROBES trial is designed to produce comparative RCT data.
4.6 Traumatic Brain Injury (TBI)
Progesterone has been associated with robust positive effects in animal models of traumatic brain injury and with clinical benefits in two phase 2 randomized, controlled trials.
The early-phase ProTECT trial was a phase II, randomized, double-blind, placebo-controlled trial conducted at an urban Level I trauma center, enrolling 100 adult trauma patients within 11 hours of injury with a Glasgow Coma Scale score of 4 to 12. Subjects were randomized on a 4:1 basis to receive either intravenous progesterone or placebo. Patients in the progesterone group demonstrated a 50% reduction in 30-day mortality compared with controls. In this small study, progesterone caused no discernible harm and showed possible signs of benefit.
To test these findings at scale, two major Phase III trials were launched. A multinational, prospective, double-blind, parallel-group SyNAPSe trial randomly assigned patients with severe TBI to intravenous progesterone or placebo, with randomization performed from July 2010 through September 2013, recruiting at level 1 or equivalent trauma centers in 21 countries. The ProTECT III trial, funded by the National Institutes of Health, was conducted in parallel but was halted on the basis of a futility analysis performed after 882 patients had undergone randomization.
The results of these Phase III trials were definitive: primary and secondary efficacy analyses of the SyNAPSe trial showed no clinical benefit of progesterone in patients with severe TBI. These data stand in contrast to the robust preclinical data and results of early single-center trials that provided the impetus to initiate Phase 3 trials.
Evidence strength: Negative. Despite promising animal and Phase 2 human data, the two large Phase 3 RCTs (SyNAPSe and ProTECT III) found no clinical benefit in severe TBI. Progesterone is not considered an established treatment for TBI.
4.7 Neuroprotection: Neuroinflammation and Neurodegeneration
Neurosteroids including progesterone have been actively studied as candidates for the treatment of neurodegenerative diseases and postinjury rehabilitation, and neuroprotective mechanisms have been shown in clinical studies of depression, epilepsy, status epilepticus, traumatic brain injury, fragile X syndrome, and chemical neurotoxicity. However, only the allopregnanolone analogs brexanolone and zuranolone have been recently approved by the FDA for the treatment of depression.
Neurosteroids are multitarget compounds with strong anti-inflammatory, immunomodulatory, and cytoprotective action; they stimulate the synthesis and release of BDNF and increase remyelination and regeneration.
Evidence strength: Preliminary-to-moderate for the broader field of neurosteroid neuroprotection; direct use of progesterone itself in neurodegenerative disease remains investigational as of the most recent literature.
4.8 Sleep Quality
Oral micronized progesterone produces neuroactive metabolites that cross the blood-brain barrier, yielding sedative effects that can improve sleep quality, particularly in postmenopausal women.
Evidence strength: Moderate; this effect is mechanistically well-explained by the GABAA-modulating activity of allopregnanolone, and has been observed in clinical settings, but is a secondary outcome in most relevant studies rather than a primary investigated endpoint.
4.9 Premenstrual Syndrome (PMS)
Historically, progesterone has been widely used in the treatment of premenstrual syndrome. Changes in concentrations of progesterone and its neuroactive metabolites are accompanied by changes in the expression of GABAA receptor subunits, and disruption of the precise synchronization of these processes can lead to premenstrual syndrome as well as other neuropsychological consequences.
Evidence strength: Weak to mixed for direct progesterone supplementation in PMS; mechanistic rationale exists, but well-controlled trials have not consistently confirmed efficacy.
4.10 Breast Pain (Mastalgia)
Clinical studies found topical progesterone to inhibit estrogen-induced proliferation of breast epithelial cells and to abolish breast pain and tenderness in women with the condition. However, in one small study in women with cyclic breast pain, it was ineffective. Vaginal progesterone has also been found to be effective in the treatment of breast pain and tenderness.
Evidence strength: Limited and inconsistent; the evidence base consists of small studies, and topical progesterone for mastalgia is approved in some countries but the clinical evidence remains inconclusive.
5. Body Systems and Health Areas
Progesterone and its metabolites act across multiple body systems:
- Reproductive system: Progesterone prepares the endometrium for implantation, prevents ovulation, and facilitates increased glandular tissue in the mammary glands.
- Central nervous system: The extent of activity of progesterone on the CNS is modulated by the route of administration — oral progesterone is affected by gut bacteria and associated enzymes, the intestinal wall, and by the liver, whereas vaginal progesterone is not.
- Immune system: Progesterone exerts significant extra-reproductive actions including immunomodulation, inhibition of cholesterol biosynthesis, and neuroprotection through multiple non-genomic signaling pathways.
- Cardiovascular system: No detrimental effects of natural progesterone in hormone therapy have been found on outcomes related to cardiovascular disease, and unlike synthetic progestins, natural progesterone does not appear to increase the risk of venous thromboembolism.
- Skeletal system: Progesterone can have important effects on a variety of tissues, including bone, the heart, and the brain.
- Neurotransmitter modulation: Progesterone and allopregnanolone can modulate the serotonergic, cholinergic, and dopaminergic neurotransmitter systems.
6. Pharmacokinetics and Dosage Forms
6.1 Oral Micronized Progesterone
Progesterone has not been administered orally in historical formulations because of reportedly poor bioavailability and a rapid clearance rate. Micronization resolved this: a standardized dose of 200 mg of micronized progesterone administered to postmenopausal women resulted in rapid absorption, with peak serum concentrations rising to 17.0 ± 4.9 ng/mL at an average of 2.8 hours after administration — equivalent to those observed in the midluteal phase of normal control cycles (14.1 ± 2.7 ng/mL). Significant elevation persisted for at least 6 hours and returned to initial levels by 24 hours.
The recommended dose of progesterone for hormone replacement treatment is 200 to 400 mg/day, given as a single evening dose. After oral administration, micronized progesterone reaches its peak plasma levels in two to three hours and has an elimination half-life of three to four hours.
Concomitant food ingestion increased the area under the serum progesterone concentration versus time curve (AUC) and the maximum serum concentration (Cmax) without affecting time to maximum serum concentration. Micronized progesterone absorption and elimination were first-order processes and exhibited dose-independent pharmacokinetics between 100 and 300 mg.
The oral route is limited by extensive first-pass hepatic metabolism, which markedly reduces its bioavailability.
6.2 Doses Reported in Specific Clinical Contexts
- An oral micronized preparation reproduces the anti-estrogenic effect on the endometrium at the dose of 200 mg daily.
- To ensure satisfactory secretory transformation of the endometrium in menopausal women receiving estrogens, patients should receive either 100 mg/day continuously or 200 mg/day sequentially for 12–14 days every cycle.
- Clinical trials have established that 100 mg oral daily, 200 mg oral sequentially, or 100 mg vaginal every second day effectively protect the endometrium.
- Acute effects of micronized progesterone on physiological, performance, and subjective measures have been investigated over a wide dose range, from 200 to 2,000 mg/day.
- Doses higher than 400 mg/day are more likely to cause sedation.
7. Safety Considerations and Drug Interactions
7.1 General Tolerability
The most common adverse effect of oral progesterone is mild sedation. Other less common adverse effects include menstrual irregularity, spotting or breakthrough bleeding, dizziness, cramps, nausea, fatigue, headache, allergic reaction, and breast tenderness.
Other side effects attributed to synthetic progestins — including depression, fluid retention, pruritus, jaundice, rash, and thrombotic disorders — have not been observed with natural progesterone.
Adverse events observed with longer-term use of micronized progesterone include mild somnolence and irregular menstrual bleeding, which are known possible side effects.
7.2 Sedation and CNS Effects
Because oral micronized progesterone produces neuroactive metabolites that cross the blood-brain barrier, it yields sedative effects. Women should be warned to use caution when driving a motor vehicle or operating machinery while undergoing treatment.
7.3 Vaginal Microbiota Considerations
Some studies suggest that prolonged use of vaginal progesterone can modify vaginal secretions and transiently reduce the abundance of Lactobacillus species, potentially causing increased discharge or discomfort.
7.4 Route-Specific Safety Differences
Natural progesterone reproduces the anti-mineralocorticoid effect and has no androgenic action. No side effects have been reported as far as lipid profile, coagulation factors, and blood pressure are concerned.
7.5 Drug Interactions
Patients on warfarin or oral anticoagulants may require an increase in anticoagulant dose. Prescribers should consider discontinuation if jaundice, visual problems, signs of venous thromboembolism, migraine of unusual severity, significant blood pressure increase, or severe depression develop. Progesterone should be discontinued four weeks before major surgery or prolonged immobilization.
7.6 Special Populations: Peanut/Sesame Allergy
A clinically important formulation note: standard oral micronized progesterone capsule formulations (e.g., Prometrium) contain peanut oil as an excipient. Patients with peanut allergy should not use such formulations — a safety consideration documented in prescribing information.
7.7 Regulatory Status and Black-Box Warning
There is a black-box warning for progesterone regarding the risk for cardiovascular disorders and breast cancer. However, it is important to note, as detailed in Section 4.5, that most of the cardiovascular and breast cancer risk data originates from studies using synthetic progestins (particularly medroxyprogesterone acetate), not natural micronized progesterone, and observational evidence consistently suggests a more favorable safety profile for natural progesterone.
Micronized progesterone is FDA-approved for hormone replacement therapy (HRT), absence of menstrual periods (amenorrhea), endometriosis, infertility treatment, and preterm delivery.
7.8 Neurosteroid Pharmacodynamics: Route Matters
The extent of activity of progesterone on the central nervous system is modulated by the route of administration: oral progesterone is affected by gut bacteria and associated enzymes secreted in the gut, the intestinal wall, and by the liver, whereas vaginal progesterone is not. This means that sedative and mood-related effects of allopregnanolone metabolites are principally an oral-route phenomenon.
References
Go back